Treatment of osteonecrosis of the femoral head with core decompression and human bone morphogenetic protein
- PMID: 15577478
- DOI: 10.1097/01.blo.0000150312.53937.6f
Treatment of osteonecrosis of the femoral head with core decompression and human bone morphogenetic protein
Abstract
A retrospective evaluation was done of 15 patients (17 hips) with symptomatic osteonecrosis of the hip treated with core decompression combined with an allogeneic, antigen-extracted, autolyzed fibula allograft and 50 mg of partially purified human bone morphogenetic protein and noncollagenous proteins. The average duration of clinical followup of the patients was 53 months (range, 26-94 months). The osteonecrotic involvement of the hip was classified by plain radiographs using a modification of the Ficat staging system and MRI evaluations. Fifteen hips were classified as Ficat Stage IIA, one hip (one patient) was classified as Ficat Stage IIB, and one hip (one patient) was classified as Ficat Stage III. Fourteen hips had involvement of 50% or less of the femoral head and 2/3 or less involvement of the weight-bearing surface of the femoral head, based on a magnetic resonance imaging evaluation. The procedures were a clinical success in 14 of 15 hips (93%; 13 patients) with Stage IIA disease. Three of 17 hips (three patients) had radiographic progression (Ficat Stages IIA, IIB, and III) of the femoral head and were converted to total hip replacements. Only one of seven hips (six patients) with 50% or less involvement of the femoral head and between 1/3 and 2/3 of the weightbearing surface of the femoral head developed radiographic progression of the femoral head. There was no radiographic progression in the 3 hips with less than 1/3 involvement of the weightbearing surface of the femoral head. Further evaluation of the potential efficacy of bone morphogenetic protein is required in randomized trials.
Similar articles
-
Free Vascularized Fibular Grafting Improves Vascularity Compared With Core Decompression in Femoral Head Osteonecrosis: A Randomized Clinical Trial.Clin Orthop Relat Res. 2017 Sep;475(9):2230-2240. doi: 10.1007/s11999-017-5374-x. Epub 2017 May 4. Clin Orthop Relat Res. 2017. PMID: 28474152 Free PMC article. Clinical Trial.
-
Survivorship analysis of hips treated with core decompression for nontraumatic osteonecrosis of the femoral head.J Bone Joint Surg Am. 1999 Feb;81(2):200-9. doi: 10.2106/00004623-199902000-00007. J Bone Joint Surg Am. 1999. PMID: 10073583
-
Comparison of early results of vascularized and non-vascularized fibular grafting in the treatment of osteonecrosis of the femoral head.Acta Orthop Traumatol Turc. 2011;45(5):326-34. doi: 10.3944/AOTT.2011.2259. Acta Orthop Traumatol Turc. 2011. PMID: 22032997
-
Core decompression of the osteonecrotic femoral head.J Bone Joint Surg Am. 1995 May;77(5):674-80. doi: 10.2106/00004623-199505000-00003. J Bone Joint Surg Am. 1995. PMID: 7744892 Review.
-
Studies of nontraumatic osteonecrosis. The role of core decompression in the treatment of nontraumatic osteonecrosis of the femoral head.Clin Orthop Relat Res. 1987 Dec;(225):104-27. Clin Orthop Relat Res. 1987. PMID: 3315373 Review.
Cited by
-
Comparison of the Efficacy of Different Combined Therapies Based on Modified Core Decompression for the Treatment of Early-stage Nontraumatic Osteonecrosis of the Femoral Head: A Retrospective Clinical Study.Orthop Surg. 2024 Aug;16(8):1912-1919. doi: 10.1111/os.14128. Epub 2024 Jun 10. Orthop Surg. 2024. PMID: 38858808 Free PMC article.
-
Allogenic Bone Graft in Dentistry: A Review of Current Trends and Developments.Int J Mol Sci. 2023 Nov 22;24(23):16598. doi: 10.3390/ijms242316598. Int J Mol Sci. 2023. PMID: 38068918 Free PMC article. Review.
-
Local BMP2 hydrogel therapy for robust bone regeneration in a porcine model of Legg-Calvé-Perthes disease.NPJ Regen Med. 2023 Sep 14;8(1):50. doi: 10.1038/s41536-023-00322-2. NPJ Regen Med. 2023. PMID: 37709818 Free PMC article.
-
Osteonecrosis of the Femoral Head. Optimizing the Early-Stage Joint-Preserving Surgical Treatment?Maedica (Bucur). 2022 Dec;17(4):948-954. doi: 10.26574/maedica.2022.17.4.948. Maedica (Bucur). 2022. PMID: 36818255 Free PMC article.
-
Local Administration of Bone Morphogenetic Protein-2 Using a Hydrogel Carrier for Robust Bone Regeneration in a Large Animal Model of Legg-Calvé-Perthes disease.Res Sq [Preprint]. 2023 Jan 17:rs.3.rs-2465423. doi: 10.21203/rs.3.rs-2465423/v1. Res Sq. 2023. Update in: NPJ Regen Med. 2023 Sep 14;8(1):50. doi: 10.1038/s41536-023-00322-2. PMID: 36711714 Free PMC article. Updated. Preprint.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
